Plain-English translation of NCT06177964 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new immunotherapy treatment called in patients whose glioblastoma (a serious brain cancer) has returned after initial treatment. The medication is delivered directly into the remaining tumor through special injections during surgery, followed by additional injections under the skin in the neck area. Researchers want to see if this approach works better or is safer than the standard chemotherapy drug currently used for recurrent glioblastoma.
Glioblastoma that comes back after initial treatment is very difficult to manage, and current chemotherapy options have limited effectiveness. This trial is exploring whether a new immunotherapy approach—delivered directly to the tumor site—might offer patients a better chance of controlling their cancer.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will first have surgery to remove as much of the recurring tumor as safely possible. During or shortly after surgery, you will receive two injections of the medication directly into the remaining tumor area (4 days apart). Starting about one week after the second injection, you will receive weekly injections under the skin in your neck area for 4 weeks, then every 3 weeks for about a year. You will have multiple MRI scans and blood tests throughout the study, and possibly a tissue biopsy 5 weeks after treatment to check how your body is responding. The entire study involvement lasts approximately 1 year, with follow-up monitoring for any serious side effects.
AI-generated summary from trial data · Aug 1, 2026 · Not medical advice
United States